Hilmar Quentmeier
Overview
Explore the profile of Hilmar Quentmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagel S, Fischer A, Bens S, Hauer V, Pommerenke C, Uphoff C, et al.
Leuk Res
. 2023 Aug;
133:107377.
PMID: 37647808
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a mature, CD30-positive T-cell lymphoma lacking expression of the anaplastic lymphoma kinase (ALK). In contrast to ALK-positive ALCL, BIA-ALCL cells express cyclin...
2.
Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma
Nagel S, Pommerenke C, Quentmeier H, Meyer C, Kaufmann M, MacLeod R
Biomedicines
. 2022 Aug;
10(8).
PMID: 36009586
Cutaneous T-cell lymphoma (CTCL) is a severe lymphoid malignancy with a worse prognosis lacking curative treatment regimens. Several gene mutations and deregulated pathways, including NFkB signaling, have been implicated in...
3.
Quentmeier H, Geffers R, Hauer V, Nagel S, Pommerenke C, Uphoff C, et al.
Sci Rep
. 2022 Jan;
12(1):1085.
PMID: 35058488
Overexpression of antiapoptotic BCL2 family proteins occurs in various hematologic malignancies and contributes to tumorigenesis by inhibiting the apoptotic machinery of the cells. Antagonizing BH3 mimetics provide an option for...
4.
Quentmeier H, Pommerenke C, Drexler H
Curr Issues Mol Biol
. 2021 Dec;
43(3):2147-2156.
PMID: 34940123
For many years, immortalized tumor cell lines have been used as reliable tools to understand the function of oncogenes and tumor suppressor genes. Today, we know that tumors can comprise...
5.
Drexler H, Nagel S, Quentmeier H
Curr Oncol
. 2021 Jun;
28(3):1790-1794.
PMID: 34068566
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that is genetically characterized by the absence of both the Philadelphia chromosome and BCR-ABL1 fusion gene and the high prevalence of...
6.
Drexler H, Quentmeier H
Int J Mol Sci
. 2020 Aug;
21(16).
PMID: 32823535
Certified cell line models provide ideal experimental platforms to answer countless scientific questions. The LL-100 panel is a cohort of cell lines that are broadly representative of all leukemia-lymphoma entities...
7.
Quentmeier H, Pommerenke C, Hauer V, Uphoff C, Zaborski M, Drexler H
Leuk Lymphoma
. 2020 Jul;
61(12):2885-2893.
PMID: 32715799
gain of function mutations (EZH2) has been implicated in the pathogenesis of B-non-Hodgkin lymphoma. The EZH2-specific inhibitor GSK126 inhibits trimethylation of histone H3K27 and induces target gene expression. However, in...
8.
Drexler H, Eberth S, Nagel S, Quentmeier H
Hemasphere
. 2020 Jan;
3(6):e315.
PMID: 31976487
No abstract available.
9.
Quentmeier H, Pommerenke C, Dirks W, Fahnrich S, Hauer V, Uphoff C, et al.
Leuk Res
. 2019 Nov;
88:106270.
PMID: 31739141
No abstract available.
10.
Stief S, Hanneforth A, Weser S, Mattes R, Carlet M, Liu W, et al.
Leukemia
. 2019 Jun;
34(1):50-62.
PMID: 31201358
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or...